Abstract
TTACROLIMUS is a potent immunosuppressant that is now well established for primary immunosuppression in kidney transplantation as well as in other solid organ transplantations, with long-term clinical experience accumulating. In Japan, tacrolimus was approved for the prevention of allograft rejection in patients receiving kidney transplants in April 1996. Since then, it has been used widely in various recipient and donor conditions. This paper summarizes the results of a 3-year experience with tacrolimus at 35 leading institutions for renal transplantation in Japan, focusing on safety data for tacrolimus with special attention to its effects on cardiovascular risk factors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
